Zhang Yunhong, Guo Qiang, Yin Xunqiang, Zhu Xiaoxiao, Zhao Lin, Zhang Zhen, Wei Ran, Wang Bin, Li Xia
School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences Laboratory for Molecular Immunology, Institute of Basic Medicine, Shandong Academy of Medical Sciences Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Medicine (Baltimore). 2018 Jun;97(26):e11276. doi: 10.1097/MD.0000000000011276.
The association of XPA rs1800975 polymorphism with breast cancers has been reported in several studies, but the results were conflicting. In order to analyze the association between XPA rs1800975 polymorphism and the risk of breast cancer, a meta-analysis was performed in the present study.
The literature search for relevant studies was conducted in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Med Online databases. The odds ratios (ORs) and their corresponding 95% confidence intervals (95% CIs) were calculated using fixed-effect/random-effects models by the STATA 12.0 software. The sources of heterogeneity were analyzed by subgroup analysis.
Six case-control studies involving 5069 subjects (2338 patients and 2731 healthy controls) were included in the present meta-analysis. In the pooled analysis, no obvious association was found between XPA rs1800975 polymorphism and the risk of breast cancer in all genetic models. However, in subgroup analysis based on ethnicity, XPA rs1800975 polymorphism was found to be related to decreased breast cancer risk in non-Asians in the recessive model (OR = 0.80, 95% CI = 0.64-1.00, P = .045). Moreover, source of control subgroup analysis demonstrated that XPA rs1800975 polymorphism might decrease the risk of breast cancer in population-based group in the recessive model (OR = 0.80, 95% CI = 0.64-1.00, P = .045).
XPA rs1800975 polymorphism may decrease the risk of breast cancer in both non-Asians and population-based patients. Large sample size and well-designed study is needed for further assessing the role of XPA polymorphism in breast cancer risk.
多项研究报道了XPA基因rs1800975多态性与乳腺癌的关联，但结果相互矛盾。为分析XPA基因rs1800975多态性与乳腺癌风险之间的关联，本研究进行了一项荟萃分析。
在PubMed、Embase、Cochrane图书馆、中国知网（CNKI）和万方医学在线数据库中检索相关研究。使用STATA 12.0软件通过固定效应/随机效应模型计算比值比（OR）及其相应的95%置信区间（95%CI）。通过亚组分析分析异质性来源。
本荟萃分析纳入了6项病例对照研究，共5069名受试者（2338例患者和2731名健康对照）。在汇总分析中，在所有遗传模型中均未发现XPA基因rs1800975多态性与乳腺癌风险之间存在明显关联。然而，在基于种族的亚组分析中，发现在隐性模型中，XPA基因rs1800975多态性与非亚洲人乳腺癌风险降低有关（OR = 0.80，95%CI = 0.64 - 1.00，P = 0.045）。此外，对照亚组分析表明，在隐性模型中，XPA基因rs1800975多态性可能会降低基于人群组的乳腺癌风险（OR = 0.80，95%CI = 0.64 - 1.00，P = 0.045）。
XPA基因rs1800975多态性可能会降低非亚洲人和基于人群的患者患乳腺癌的风险。需要大样本量和设计良好的研究来进一步评估XPA多态性在乳腺癌风险中的作用。
